RESEARCH - Substance Use Disorder

Osmotic-Release Methylphenidate (OROS MPH) for
Attention Deficit Hyperactivity Disorder in Adolescents
with Substance-Use Disorders

Principal Investigator: Geetha Subramaniam, M.D.

This is a multi-site randomized controlled trial sponsored by the National Institute on Drug Abuse. The primary objective of this study is to evaluate the efficacy of OROS-MPH(Concerta) relative to placebo, in treating Attention Deficit Hsypeactivity Disorder (ADHD) and decreasing substance use in adolescents ages 13-18 years with ADHD and a substance-use disorder (SUD). Secondary objectives include evaluating the safety and abuse liability of OROS-MPH in the treatment of adolescents with ADHD and a SUD and evaluating the impact of treating ADHD with OROS-MPH on substance-use treatment outcomes and psychosocial functioning. All study participants will receive standardized treatment for SUD consisting of weekly, standardized cognitive-behavioral-therapy (CBT) sessions. 

Buprenorphine Detoxification for Adolescents and Young Adults
at a Community-based Residential Treatment Program

Principal Investigator: Geetha Subramaniam, M.D.

This project is a retrospective chart review of adolescents and young adults who have received detoxification treatment for current opioid use disorder in residential treatment.  The primary objective is to compare the clinical and treatment characteristics of adolescents and young adults with opioid use disorder receiving buprenorphine detoxification during residential treatment at Moutain Manor Treatment Center from January 2005 – June 2006 with those who received previously available detoxification treatments (e.g. methadone, clonidine) in the previous year (i.e., January 2004-December 2005). Additional objectives are to compare differences in outcome based on available data (e.g., rates of against medical advice discharges from residential treatment and rates of readmission).